Ellevest Inc’s Phathom Pharmaceuticals PHAT Stock Holding History

Ellevest Inc’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12	Closed	–	–	1938
2022 Q3	$0	Buy	+12	New	+$114	﹤0.01%	1794

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Ellevest Inc's PHAT Position: Q4 2022 in Review

Ellevest Inc sold out of Phathom Pharmaceuticals (PHAT) in Q4 2022, closing a stake of 12 shares.

Ellevest Inc first reported a position in PHAT in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 87 funds tracked by Wall St. Rank hold PHAT as of Q4 2022.

Ellevest Inc reported no remaining Phathom Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ellevest Inc sold 12 Phathom Pharmaceuticals shares in Q4 2022.
Ellevest Inc first reported a position in Phathom Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Ellevest Inc's Phathom Pharmaceuticals position peaked at $0 in Q3 2022.
87 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2022.

Based on Ellevest Inc's 13F filing for Q4 2022, filed 3 Feb 2023.